Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis

Rick Dersch*, Antonia A. Sarnes, Monika Maul, Tilman Hottenrott, Annette Baumgartner, Sebastian Rauer, Oliver Stich

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

The prognosis and impact of residual symptoms on quality of life in patients with Lyme neuroborreliosis (LNB) is subject to debate. The aim of this study was to assess quality of life, fatigue, depression, cognitive impairment and verbal learning in patients with definite LNB and healthy controls in a case–control study. We retrospectively identified all patients diagnosed with definite LNB between 2003 and 2014 in our tertiary care center. Healthy controls were recruited from the same area. Patients and healthy controls were assessed for quality of life [Short Form (36) with subscores for physical and mental components (PCS, MCS)], fatigue (fatigue severity scale), depression (Beck depression inventory), verbal memory and learning and cognitive impairment (mini-mental state examination). 53 patients with definite LNB could be identified, of which 30 partook in the follow-up assessment. Estimates for quality of life, fatigue, depression, verbal memory and cognitive impairment did not differ statistically significantly between 30 patients with LNB and 35 healthy controls. Patients with residual symptoms had lower scores for quality of life (PCS) compared to patients without residual symptoms. Our results do not support the hypothesis that a considerable proportion of patients with antibiotically treated LNB develop a ‘post Lyme syndrome’ consisting of debilitating fatigue or cognitive impairment or have severe limitations of quality of life. However, some patients experience residual symptoms of LNB.

OriginalspracheEnglisch
ZeitschriftJournal of Neurology
Jahrgang262
Ausgabenummer11
Seiten (von - bis)2572-2577
Seitenumfang6
ISSN0340-5354
DOIs
PublikationsstatusVeröffentlicht - 01.11.2015

Fördermittel

RD, AS, MM, TH and AB have nothing to declare. SR reports receiving consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, Baxter, RG, and Teva. Furthermore, SR indicates that he is a founding executive board member of ravo Diagnostika GmbH. All other authors declare that they have no competing interests. OS reports receiving consulting and lecture fees, grant and research support from Baxter, Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, RG, Sanofi-Aventis and Teva.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Querschnittsbereich: Gesundheitswissenschaften: Logopädie, Ergotherapie, Physiotherapie und Hebammenwissenschaft

DFG-Fachsystematik

  • 2.23-07 Klinische Neurologie, Neurochirurgie und Neuroradiologie
  • 2.22-02 Public Health, gesundheitsbezogene Versorgungsforschung, Sozial- und Arbeitsmedizin

Fingerprint

Untersuchen Sie die Forschungsthemen von „Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren